Abstract Library

#4593 Excellent response to Ac-225 DOTATATE therapy in a patient with small cell lung cancer

Introduction: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for patients with NETs overexpressing somatostatin receptors (SSTR). IHC analysis indicates that up to 50% of small cell lung cancer (SCLC) tumours are SSTR2 positive and thus can be targeted by SSR imaging and PRRT. Therapy with α-emitting radionuclides, such as Ac225, may offer several advantages over β-emitters by having higher energy transfer and more effective cancer cell death.

Conference:

Presenting Author: Tuncel M

Authors: Tuncel M, Türkan C, Eryılmaz Y, Pala A, Kılıçkap S,

Keywords: Ac-225 DOTATATE, Small Cell lung cancer, PET, somatostatin receptor, PRRT,

#3472 Reduction of 64Cu-DOTATATE activity dose for somatostatin receptor PET imaging of patients with neuroendocrine neoplasms

Introduction: Frequent somatostatin receptor (SSR) PET imaging is key in the clinical management of patients with neuroendocrine neoplasms (NEN) and measures to reduce the radiation exposure should be pursued.

Conference:

Presenting Author:

Authors: Loft M, Carlsen E, Johnbeck C, Jensen C, Andersen F,

Keywords: 64Cu-DOTATATE, neuroendocrine neoplasm, PET imaging, SSR imaging,

#1916 Circulating Neuroendocrine Transcripts and Gene Cluster Analysis Predict the Efficacy of PRRT

Introduction: Prediction of PRRT efficacy is critical. We tested a blood-based multigene NET transcript analysis (NETest) to predict efficacy in 2 PRRT-treated NET cohorts. The algorithm comprises >50 genes + clusters of growth factor signaling (GFS) and metabolism (MTB).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Bodei L

Authors: Bodei L, Kidd M, Singh A, Severi S, Drozdov I,

Keywords: PRRT, efficacy,